论文部分内容阅读
目的:探讨新型β受体阻滞剂卡维地洛对老年慢性心力衰竭的疗效和对糖、脂代谢的影响。方法:60例年龄65岁以上慢性心力衰竭伴糖尿病病人(男性53例,女性7例),随机分为卡维地洛+常规抗心力衰竭治疗组(卡维地洛组30例)和单纯常规抗心力衰竭治疗组(对照组30例)。两组的血压、心率、血糖、血脂无差别。卡维地洛初始剂量3.125mg1日3次;1～2周剂量递增,至25mg1日3次,共12周。结果:两组治疗后收缩压和舒张压较治疗前显著降低,心率减慢。卡维地洛组和对照组治疗后空腹血糖和餐后2小时血糖及血脂均较治疗前显著减低。结论:卡维地洛对糖、脂代谢无不良影响,对伴有糖尿病的老年慢性心力衰竭的治疗安全、有效。
Objective: To investigate the effect of a new type of beta-blocker carvedilol on senile chronic heart failure and its effect on metabolism of glucose and lipid. Methods: Sixty elderly patients with chronic heart failure and diabetes mellitus aged 65 years and older (53 males and 7 females) were randomly divided into carvedilol and conventional anti-heart failure treatment group (30 cases of carvedilol group) and simple routine Anti-heart failure treatment group (control group 30 cases). Two groups of blood pressure, heart rate, blood glucose, blood lipids no difference. Carvedilol initial dose 3.125mg1 3 times a day; 1 to 2 weeks dose escalation to 25mg1 3 times a total of 12 weeks. Results: After treatment, the systolic and diastolic blood pressures decreased significantly and the heart rate slowed down after treatment. Carvedilol group and control group after treatment, fasting blood glucose and 2-hour postprandial blood glucose and blood lipids were significantly lower than before treatment. Conclusion: Carvedilol has no adverse effect on glucose and lipid metabolism, and is safe and effective in the treatment of elderly chronic heart failure with diabetes.